Correction to: Crisaborole Ointment, 2%, for Treatment of Patients with Mild-to-Moderate Atopic Dermatitis: Systematic Literature Review and Network Meta-Analysis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2190-9172
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Correction to: Crisaborole Ointment, 2%, for Treatment of Patients with Mild-to-Moderate Atopic Dermatitis: Systematic Literature Review and Network Meta-Analysis ; volume:10 ; number:6 ; day:6 ; month:10 ; year:2020 ; pages:1441-1444 ; date:12.2020
Dermatology and therapy ; 10, Heft 6 (6.10.2020), 1441-1444, 12.2020
- Creator
-
Fahrbach, Kyle
Tarpey, Jialu
Washington, Evelien Bergrath
Hughes, Rachel
Thom, Howard
Neary, Maureen P.
Cha, Amy
Gerber, Robert
Cappelleri, Joseph C.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s13555-020-00452-1
- URN
-
urn:nbn:de:101:1-2020122018545327022280
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:26 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Fahrbach, Kyle
- Tarpey, Jialu
- Washington, Evelien Bergrath
- Hughes, Rachel
- Thom, Howard
- Neary, Maureen P.
- Cha, Amy
- Gerber, Robert
- Cappelleri, Joseph C.
- SpringerLink (Online service)
Other Objects (12)
Impact of Crisaborole on Sleep Outcomes in Pediatric Patients with Mild-to-Moderate Atopic Dermatitis
Subgroup Analysis of Crisaborole for Mild-to-Moderate Atopic Dermatitis in Children Aged 2 to < 18 Years
Correction to: Baricitinib: A Review in Moderate to Severe Atopic Dermatitis
Crisaborole Ointment, 2%, for Treatment of Patients with Mild-to-Moderate Atopic Dermatitis: Systematic Literature Review and Network Meta-Analysis
Clinical and Economic Burden of Mild-to-Moderate Atopic Dermatitis in the UK: A Propensity-Score-Matched Case–Control Study
Clinical and Economic Burden of Pediatric Mild-to-Moderate Atopic Dermatitis: A Population-Based Nested Case–Control Study in Sweden
Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis
Efficacy and Safety of Crisaborole Ointment, 2%, for the Treatment of Mild-to-Moderate Atopic Dermatitis Across Racial and Ethnic Groups
Efficacy and Safety Trends with Continuous, Long-Term Crisaborole Use in Patients Aged ≥ 2 Years with Mild-to-Moderate Atopic Dermatitis
Correction to: Efficacy and Safety Trends with Continuous, Long-Term Crisaborole Use in Patients Aged ≥ 2 Years with Mild-to-Moderate Atopic Dermatitis
Ruxolitinib Cream 1.5%: A Review in Mild to Moderate Atopic Dermatitis
Correction to: Ruxolitinib Cream 1.5%: A Review in Mild to Moderate Atopic Dermatitis
Impact of Crisaborole on Sleep Outcomes in Pediatric Patients with Mild-to-Moderate Atopic Dermatitis
Subgroup Analysis of Crisaborole for Mild-to-Moderate Atopic Dermatitis in Children Aged 2 to < 18 Years
Correction to: Baricitinib: A Review in Moderate to Severe Atopic Dermatitis
Crisaborole Ointment, 2%, for Treatment of Patients with Mild-to-Moderate Atopic Dermatitis: Systematic Literature Review and Network Meta-Analysis
Clinical and Economic Burden of Mild-to-Moderate Atopic Dermatitis in the UK: A Propensity-Score-Matched Case–Control Study
Clinical and Economic Burden of Pediatric Mild-to-Moderate Atopic Dermatitis: A Population-Based Nested Case–Control Study in Sweden
Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis
Efficacy and Safety of Crisaborole Ointment, 2%, for the Treatment of Mild-to-Moderate Atopic Dermatitis Across Racial and Ethnic Groups
Efficacy and Safety Trends with Continuous, Long-Term Crisaborole Use in Patients Aged ≥ 2 Years with Mild-to-Moderate Atopic Dermatitis
Correction to: Efficacy and Safety Trends with Continuous, Long-Term Crisaborole Use in Patients Aged ≥ 2 Years with Mild-to-Moderate Atopic Dermatitis
Ruxolitinib Cream 1.5%: A Review in Mild to Moderate Atopic Dermatitis
Correction to: Ruxolitinib Cream 1.5%: A Review in Mild to Moderate Atopic Dermatitis
Impact of Crisaborole on Sleep Outcomes in Pediatric Patients with Mild-to-Moderate Atopic Dermatitis
Subgroup Analysis of Crisaborole for Mild-to-Moderate Atopic Dermatitis in Children Aged 2 to < 18 Years
Correction to: Baricitinib: A Review in Moderate to Severe Atopic Dermatitis
Crisaborole Ointment, 2%, for Treatment of Patients with Mild-to-Moderate Atopic Dermatitis: Systematic Literature Review and Network Meta-Analysis
Clinical and Economic Burden of Mild-to-Moderate Atopic Dermatitis in the UK: A Propensity-Score-Matched Case–Control Study
Clinical and Economic Burden of Pediatric Mild-to-Moderate Atopic Dermatitis: A Population-Based Nested Case–Control Study in Sweden
Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis
Efficacy and Safety of Crisaborole Ointment, 2%, for the Treatment of Mild-to-Moderate Atopic Dermatitis Across Racial and Ethnic Groups
Efficacy and Safety Trends with Continuous, Long-Term Crisaborole Use in Patients Aged ≥ 2 Years with Mild-to-Moderate Atopic Dermatitis
Correction to: Efficacy and Safety Trends with Continuous, Long-Term Crisaborole Use in Patients Aged ≥ 2 Years with Mild-to-Moderate Atopic Dermatitis
Ruxolitinib Cream 1.5%: A Review in Mild to Moderate Atopic Dermatitis